Acadian Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.52M | Sell |
7,719
-1,258
| -14% | -$410K | 0.01% | 760 |
|
|
2025
Q1 | $2.42M | Sell |
8,977
-7,699
| -46% | -$2.08M | 0.01% | 709 |
|
|
2024
Q4 | $3.92M | Sell |
16,676
-17,741
| -52% | -$4.17M | 0.01% | 588 |
|
|
2024
Q3 | $9.46M | Sell |
34,417
-2,893
| -8% | -$795K | 0.03% | 354 |
|
|
2024
Q2 | $9.06M | Buy |
37,310
+35,651
| +2,149% | +$8.66M | 0.03% | 375 |
|
|
2024
Q1 | $247K | Buy |
1,659
+386
| +30% | +$57.5K | ﹤0.01% | 1154 |
|
|
2023
Q4 | $243K | Buy |
1,273
+369
| +41% | +$70.4K | ﹤0.01% | 1197 |
|
|
2023
Q3 | $160K | Buy |
904
+311
| +52% | +$55K | ﹤0.01% | 1235 |
|
|
2023
Q2 | $112K | Buy |
+593
| New | +$112K | ﹤0.01% | 1384 |
|
|
2023
Q1 | – | Sell |
-917
| Closed | -$217K | – | 1722 |
|
|
2022
Q4 | $217K | Hold |
917
| – | – | ﹤0.01% | 1264 |
|
|
2022
Q3 | $182K | Buy |
+917
| New | +$182K | ﹤0.01% | 1233 |
|